

JOURNAL OF HEPATOLOGY

The Home of Liver Research

VOLUME 70, ISSUE 6, PAGES 1039–1306

FROM THE EDITOR'S DESK

From the Editor's desk. . .

R. Moreau, R. Bataller, T. Berg, S. Lotersztajn, J. Zucman-Rossi and R. Jalan 1039

EDITORIALS

Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa

G. Umutesi, F. Shumbusho, F. Kateera, J. Serumondo, J. Kabahizi, E. Musabeyezu, A. Ngwije, N. Gupta and S. Nsanzimana 1043

An appraisal of the WHO hepatitis B treatment guidelines applicability to Africans

G. Dusheiko and M. Lemoine 1046

Hepatocyte transplantation, a step forward?

M. Ott and J.V. Castell 1049

Biliary-derived hepatocytes in chronic liver injury: Bringing new troops to the battlefield?

N. Aleksieva and S.J. Forbes 1051

Hedgehog signaling keeps liver clock in check

G. Mazzocchi, A. Keshavarzian and M. Vinciguerra 1054

Individualized medicine comes to the liver clinic

F. Pinto e Vairo and K.N. Lazaridis 1057

Trial endpoints for systemic therapy in patients with hepatocellular carcinoma

T. Meyer and P. Johnson 1060

Progression-free survival: Starting point or endpoint in advanced HCC trial design?

R.S. Finn 1062

RESEARCH ARTICLES

Viral Hepatitis

The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia

H. Abera, H. Desalegn, N. Berhe, B. Mekasha, G. Medhin, S.G. Gundersen and A. Johannessen 1065

ERAP1 allotypes shape the epitope repertoire of virus-specific CD8⁺ T cell responses in acute hepatitis C virus infection

J. Kemming, E. Reeves, K. Nitschke, V. Widmeier, F. Emmerich, T. Hermle, E. Gostick, A. Walker, J. Timm, D.A. Price, M. Hofmann, R. Thimme, E. James and C. Neumann-Haefelin 1072

A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors

D.H. Banda, P.M. Perin, R.J.P. Brown, D. Todt, W. Solodenko, P. Hoffmeyer, K. Kumar Sahu, M. Houghton, P. Meuleman, R. Müller, A. Kirschning and T. Pietschmann 1082

Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients

E.-S. Park, A.R. Lee, D.H. Kim, J.-H. Lee, J.-J. Yoo, S.H. Ahn, H. Sim, S. Park, H.S. Kang, J. Won, Y.N. Ha, G.-C. Shin, S.Y. Kwon, Y.K. Park, B.-S. Choi, Y.B. Lee, N. Jeong, Y. An, Y.S. Ju, S.J. Yu, H.B. Chae, K.-S. Yu, Y.J. Kim, J.-H. Yoon, F. Zoulim and K.-H. Kim 1093

OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection

F.J. Jacobi, K. Wild, M. Smits, K. Zoldan, B. Csernalabics, T. Flecken, J. Lang, P. Ehrenmann, F. Emmerich, M. Hofmann, R. Thimme, C. Neumann-Haefelin and T. Boettler 1103

Transplantation

Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis

T.C.-L. Wong, J.Y.-Y. Fung, T.Y.-S. Cui, A.H.-K. Lam, J.W.-C. Dai, A.C.-Y. Chan, T.-T. Cheung, K.S.-H. Chok, K.K.-C. Ng and C.-M. Lo 1114

Cancer

Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome

M. Van Wettere, Y. Purcell, O. Bruno, A. Payancé, A. Plessier, P.-E. Rautou, D. Cazals-Hatem, D. Valla, V. Vilgrain and M. Ronot 1123

Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma

X. Xu, H.-L. Zhang, Q.-P. Liu, S.-W. Sun, J. Zhang, F.-P. Zhu, G. Yang, X. Yan, Y.-D. Zhang and X.-S. Liu 1133

Molecular and Cell Biology

Generation of hepatobiliary organoids from human induced pluripotent stem cells

F. Wu, D. Wu, Y. Ren, Y. Huang, B. Feng, N. Zhao, T. Zhang, X. Chen, S. Chen and A. Xu 1145

Nucleotide-binding oligomerization domain 1 (NOD1) modulates liver ischemia reperfusion through the expression adhesion molecules

G. Lassailly, M. Bou Saleh, N. Leleu-Chavain, M. Ningharhari, E. Gantier, R. Carpentier, F. Artru, V. Gnemmi, B. Bertin, P. Maboudou, D. Betbeder, C. Gheeraert, F. Maggiotto, S. Dharancy, P. Mathurin, A. Louvet and L. Dubuquoy 1159

Radiation-primed hepatocyte transplantation in murine monogenic dyslipidemia normalizes cholesterol and prevents atherosclerosis

M. Barahman, W. Zhang, H.Y. Harris, A. Aiyer, R. Kabarriti, M. Kinkhabwala, N. Roy-Chowdhury, A.P. Beck, T.S. Scanlan, J. Roy-Chowdhury, P. Asp and C. Guha 1170

Reactive cholangiocytes differentiate into proliferative hepatocytes with efficient DNA repair in mice with chronic liver injury

R. Manco, L.-A. Clerbaux, S. Verhulst, M. Bou Nader, C. Sempoux, J. Ambroise, B. Bearzatto, J.L. Gala, Y. Horsmans, L. van Grunsven, C. Desdouets and I. Leclercq 1180

Genetic and Metabolic Diseases

Tick-tock hedgehog-mutual crosstalk with liver circadian clock promotes liver steatosis

E. Marbach-Breitrück, M. Matz-Soja, U. Abraham, W. Schmidt-Heck, S. Sales, C. Rennert, M. Kern, S. Aleithe, L. Spormann, C. Thiel, R. Gerlini, K. Arnold, N. Klötting, R. Guthke, D. Rozman, R. Teperino, A. Shevchenko, A. Kramer and R. Gebhardt 1192

The degree of hepatic steatosis associates with impaired cardiac and autonomic function

D. Houghton, P. Zalewski, K. Hallsworth, S. Cassidy, C. Thoma, L. Avery, J. Slomko, T. Hardy, A.D. Burt, D. Tiniakos, K.G. Hollingsworth, R. Taylor, C.P. Day, S. Masson, S. M^cPherson, Q.M. Anstee, J.L. Newton and M.I. Trenell 1203

Clinical utility of genomic analysis in adults with idiopathic liver disease

A. Hakim, X. Zhang, A. DeLisle, E.A. Oral, D. Dykas, K. Drzewiecki, D.N. Assis, M. Silveira, J. Batisti, D. Jain, A. Bale, P.K. Mistry and S. Vilarinho 1214

CLINICAL PRACTICE GUIDELINES

EASL Clinical Practice Guidelines: Drug-induced liver injury

R.J. Andrade 1222

REVIEWS

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

J.M. Llovet, R. Montal and A. Villanueva 1262

Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease

A. Hammoutene and P.-E. Rautou 1278

SPECIAL SECTION

Hepatology Snapshot

Extracellular vesicles, the liquid biopsy of the future

A. Eguchi, E. Kostallari, A.E. Feldstein and V.H. Shah 1292

LETTERS TO THE EDITOR

Clinical utility of TREAT-B score in African and non-African HBV-infected patients living in Europe

K. Yoshida, G. Post, Y. Shimakawa, M. Thursz, A. Brown, P. Ingiliz and M. Lemoine 1295

Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference

L. Mouna, E. Rossignol, M. Tateo, A. Coilly, J.-C. Duclos-Vallée, C. Duvoux, F. Durand, A. Tran, S. Radenne, V. Canva-Delcambre, P. Housset-Debry, J. Dumortier, F. Conti, V. de Ledinghen, V. Leroy, N. Kamar, V. Di Martino, C. Moreno, D. Botta Fridlund, L. d'Alteroche, P. Lebray, P. Perre, C. Besch, C. Silvain, F. Habersetzer, M. Debette-Gratien, A. Abergel, A. Diallo, D. Samuel, A.-M. Roque-Afonso, G.-P. Pageaux and the ANRS CO23 CUPILT study group 1297

Mortality of acute-on-chronic liver failure: What is the role of obesity?

V. Sundaram 1301

Reply to: "Mortality of acute-on-chronic liver failure: What is the role of obesity?"

R. Hernaez, J.R. Kramer, Y. Liu and F. Kanwal 1301

NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter

L.J.M. Alferink and S. Darwish Murad 1302

Reply to: "NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter"

V.W.-S. Wong and H.L.-Y. Chan 1304

Comment on the article "Age and liver transplantation"

F. Ferla, A. Lauterio, R. De Carlis, S. Di Sandro, N. Petrucciani, L. Benuzzi and L. De Carlis 1305

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

Cover image: Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival, by J.M. Llovet et al. on pp. 1262–1277 in this issue.

Cover design: Wandering a maze of survival outcome measures. By Caitlin Monney.